| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 1,764 | 2,200 | 2,457 | 2,130 | 2,103 | 2,642 | 2,772 | 2,682 | 2,517 | 2,976 | 3,173 | 3,286 | 3,333 | 3,653 | 3,791 | 3,643 | 3,560 | 4,080 |
| Expenses | 1,441 | 1,724 | 1,835 | 1,654 | 1,636 | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,217 | 2,383 | 2,401 | 2,724 | 2,776 | 2,754 | 2,536 | 2,974 |
| EBITDA | 323 | 476 | 622 | 477 | 467 | 718 | 746 | 681 | 681 | 780 | 956 | 903 | 933 | 930 | 1,016 | 889 | 1,024 | 1,105 |
| Operating Profit % | 17 % | 21 % | 24 % | 21 % | 20 % | 25 % | 25 % | 23 % | 24 % | 23 % | 28 % | 26 % | 22 % | 24 % | 25 % | 23 % | 26 % | 26 % |
| Depreciation | 47 | 78 | 79 | 85 | 85 | 87 | 97 | 110 | 100 | 103 | 101 | 187 | 231 | 219 | 222 | 223 | 223 | 226 |
| Interest | 13 | 16 | 10 | 13 | 5 | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 | 110 |
| Profit Before Tax | 263 | 382 | 533 | 379 | 377 | 625 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 541 | 624 | 509 | 659 | 770 |
| Tax | 70 | 84 | 110 | 83 | 84 | 130 | 130 | 103 | 95 | 123 | 190 | 111 | 86 | 96 | 104 | 95 | 100 | 195 |
| Net Profit | 193 | 298 | 423 | 296 | 294 | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 |
| EPS in ₹ | 4.74 | 7.30 | 10.48 | 7.09 | 7.13 | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.46 | 10.19 | 10.62 | 12.39 | 9.90 | 13.44 | 13.76 |
Mankind Pharma
Mankind Pharma
2,575.90
-16.80
(-0.65%)
Market Cap
1,06,383.63 Cr
PE Ratio
55.24
Volume
2,94,648.00
Day High - Low
2,605.00 - 2,560.50
52W High-Low
2,674.00 - 1,909.70
Key Fundamentals
Market Cap
1,06,383.63 Cr
EPS
46.35
PE Ratio
55.24
PB Ratio
6.57
Book Value
394.69
EBITDA
3,976.20
Dividend Yield
0.04 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
11.70
Debt to Equity
0.48
Analyst Rating and Forecast
- By Refinitiv from18 analysts
Actual
Company News
View All News
Mankind Pharma reported a 34% YoY rise in consolidated net profit to ₹574.09 crore for Q1FY26, driven by 13% revenue growth. The Board also approved a ₹150 crore corporate guarantee for subsidiary BSV.
Mankind Pharma Q1 Results: Net Profit Up to ₹5.7BToday
Mankind Pharma reports Q1 net profit of ₹5.7B rupees vs ₹4.4B YoY, with EBITDA rising to ₹10.6B and EBITDA margin expanding to 26.2% from 23.7%.
Mankind Pharma: ₹18.34 Cr Block Trade on NSE2 days ago
Mankind Pharma sees a block trade of ~71,310 shares on NSE at ₹2572.00 per share, aggregating to ₹18.34 crores.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
2,001.10 | #1 4,80,130.92 | 41.48 | #1 61,673.90 | 12.69 | #1 11,565 | 25.80 | 70.23 | |
7,835.00 | 2,07,994.63 | 80.57 | 11,067.00 | 13.95 | 2,568 | 13.44 | 78.93 | |
4,872.10 | 1,85,319.02 | 86.77 | 13,886.20 | 20.34 | 2,138 | -26.91 | 52.19 | |
1,466.40 | 1,18,462.44 | 35.47 | 29,044.60 | 2.24 | 3,870 | -39.18 | 60.03 | |
1,115.10 | 1,12,205.15 | 21.85 | 27,657.90 | 17.64 | 5,026 | 7.82 | 49.15 | |
2,421.20 | 1,10,705.14 | #1 20.92 | 29,038.90 | #1 26.75 | 5,356 | 87.72 | 50.28 | |
2,575.90 | #7 1,06,383.63 | #7 55.24 | #7 14,636.40 | #5 14.85 | #9 1,938 | #3 31.75 | 56.18 | |
1,781.30 | 96,164.65 | 88.29 | 6,867.80 | 22.01 | 890 | #1 123.93 | 79.83 | |
1,144.80 | 95,552.92 | 29.97 | 35,058.60 | 3.90 | 4,158 | -69.10 | 27.15 | |
1,576.30 | 90,696.82 | 26.38 | 33,384.70 | 3.21 | 3,376 | 1.99 | 56.67 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
14.85 %
Net Income Growth
-3.41 %
Cash Flow Change
29.33 %
ROE
-15.03 %
ROCE
3.38 %
EBITDA Margin (Avg.)
-2.58 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 | 28,080 |
| Fixed Assets | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 | 18,621 |
| Current Assets | 3,907 | 4,407 | 4,328 | 6,568 | 6,988 | 6,954 |
| Capital Work in Progress | 372 | 702 | 550 | 282 | 826 | 1,128 |
| Investments | 1,512 | 1,110 | 1,346 | 2,568 | 2,042 | 1,985 |
| Other Assets | 2,824 | 3,749 | 3,568 | 4,568 | 5,887 | 6,346 |
| Total Equity & Liabilities | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 | 28,080 |
| Current Liabilities | 1,353 | 2,624 | 1,863 | 2,120 | 5,664 | 6,507 |
| Non Current Liabilities | 156 | 208 | 229 | 268 | 7,528 | 5,011 |
| Total Equity | 4,863 | 6,316 | 7,623 | 9,576 | 14,568 | 16,561 |
| Reserve & Surplus | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 | 16,259 |
| Share Capital | 40 | 40 | 40 | 40 | 41 | 41 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 | 22 | -12 |
| Investing Activities | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 | -181 |
| Operating Activities | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 | 3,121 |
| Financing Activities | -531 | -8 | 605 | -740 | 5 | 10,233 | -2,953 |
Share Holding
| % Holding | Sept 2022 | Mar 2023 | May 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 79.00 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 74.88 % | 74.87 % | 74.87 % | 72.71 % | 72.70 % | 72.68 % | 72.67 % | 72.66 % | 72.66 % | 72.63 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 9.87 % | 11.58 % | 12.37 % | 13.34 % | 12.92 % | 13.07 % | 12.84 % | 11.34 % | 10.24 % | 9.45 % |
| DIIs | 0.00 % | 2.64 % | 2.64 % | 4.64 % | 4.39 % | 9.49 % | 11.14 % | 9.95 % | 9.90 % | 11.06 % | 11.48 % | 11.50 % | 11.92 % | 13.25 % | 14.46 % | 15.39 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.15 % | 4.15 % | 1.02 % | 1.11 % | 1.14 % | 1.22 % | 1.46 % | 1.55 % | 1.60 % | 1.64 % | 1.52 % | 1.36 % | 1.52 % | 1.39 % | 1.29 % |
| Others | 21.00 % | 16.71 % | 16.71 % | 17.83 % | 18.00 % | 12.87 % | 2.89 % | 2.15 % | 1.31 % | 1.30 % | 1.26 % | 1.23 % | 1.21 % | 1.23 % | 1.25 % | 1.24 % |
| No of Share Holders | 17 | 4,02,322 | 4,02,322 | 1,31,918 | 1,34,731 | 1,27,449 | 1,35,116 | 1,53,450 | 1,63,854 | 1,72,431 | 1,80,597 | 1,79,549 | 1,70,347 | 1,77,539 | 1,77,606 | 1,66,715 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 04 Aug 2026 |  Annual General Meeting | NA | 04 Aug 2026 | 2,485.30 | 2,592.55 |
| 30 Jul 2026 |  Quarterly Result Announcement | NA | 30 Jul 2026 | 2,546.60 | 2,592.55 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 2,114.50 | 2,068.60 |
| 05 Nov 2024 | Quarterly Result Announcement | NA | 05 Nov 2024 | 2,504.25 | 2,734.95 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 2,738.25 | 2,515.05 |
| 21 May 2025 | Quarterly Result Announcement | NA | 21 May 2025 | 2,432.40 | 2,550.70 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 2,578.00 | 2,575.50 |
| 07 Aug 2025 | Annual General Meeting | NA | 07 Aug 2025 | 2,384.70 | 2,553.25 |
| 08 Aug 2025 |  Dividend | ₹ 1.00 /share | 08 Aug 2025 | 2,575.50 | 2,537.80 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 2,432.40 | 2,369.35 |
| 03 Feb 2026 | Quarterly Result Announcement | NA | 03 Feb 2026 | 2,261.20 | 2,063.80 |
| 19 May 2026 | Quarterly Result Announcement | NA | 19 May 2026 | 2,361.90 | 2,496.35 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
50 mins ago
50 mins agoCompliances-Reg. 54 - Asset Cover details 5 hrs ago
5 hrs agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release5 hrs ago
5 hrs agoAnnouncement under Regulation 30 (LODR)-Investor Presentation5 hrs ago
5 hrs agoApproval For Issuance Of Corporate Guarantee5 hrs ago
5 hrs agoUn-Audited Financial Results Of The Company For The Quarter Ended On June 30 20265 hrs ago
5 hrs agoBoard Meeting Outcome for Outcome Of Board Meeting5 hrs ago
5 hrs agoFinal Update On Stake Sale Of Broadway Hospitality Services Private Limited3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 17, 2026
Jul 17, 2026Board Meeting Intimation for Approval Of Financial ResultsJul 16, 2026
Jul 16, 2026Announcement under Regulation 30 (LODR)-Diversification / DisinvestmentJul 11, 2026
Jul 11, 2026Announcement under Regulation 30 (LODR)-AcquisitionJul 11, 2026
Jul 11, 2026Board Meeting Outcome for Outcome Of Board MeetingJul 11, 2026
Jul 11, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2026
Jul 10, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 10, 2026
Jul 10, 2026Business Responsibility and Sustainability Reporting (BRSR)Jul 09, 2026
Jul 09, 2026Regulation 53 (1) Annual Report.Jul 09, 2026
Jul 09, 2026Reg. 34 (1) Annual Report.Jul 09, 2026
Jul 09, 2026Notice Of 35Th AGMJul 09, 2026
Jul 09, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 01, 2026
Jul 01, 2026Intimation Of Date Of AGMJun 30, 2026
Jun 30, 2026Closure of Trading WindowJun 25, 2026
Jun 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 15, 2026
Jun 15, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJun 08, 2026
Jun 08, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 08, 2026
Jun 08, 2026Announcement under Regulation 30 (LODR)-AcquisitionJun 02, 2026
Jun 02, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2026
May 27, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 20, 2026
May 20, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-AcquisitionMay 19, 2026
May 19, 2026Board Meeting Outcome for Please Find Attached The Audited Financial Results For The Quarter And Financial Year Ended March 31 2026May 19, 2026
May 19, 2026Financial Results For The Quarter And Financial Year Ended March 31 2026May 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Credit RatingMay 12, 2026
May 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2026
May 08, 2026Board Meeting Intimation for Inter Alia Consider And Approve The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended On March 31 2026 And Realignment Of Security Cover Provided In Respect Of ExistiMay 07, 2026
May 07, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 06, 2026
May 06, 2026Announcement under Regulation 30 (LODR)-Credit RatingApr 22, 2026
Apr 22, 2026Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD Apr 16, 2026
Apr 16, 2026Announcement under Regulation 30 (LODR)-RestructuringApr 13, 2026
Apr 13, 2026Board Meeting Outcome for Outcome Of Board MeetingApr 13, 2026
Apr 13, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 06, 2026
Apr 06, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 18, 2026
Mar 18, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 16, 2026
Mar 16, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 58.33
ATR(14)
Less Volatile 66.30
STOCH(9,6)
Neutral 55.31
STOCH RSI(14)
Neutral 73.44
MACD(12,26)
Bullish 1.36
ADX(14)
Strong Trend 27.25
UO(9)
Bearish 50.93
ROC(12)
Uptrend And Accelerating 3.40
WillR(14)
Neutral -28.58
About Mankind Pharma
Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since...more
Listing Date
09 May, 2023(3 Years, 2 Months, 21 Days)
Chairperson NameRAMESH CHAND JUNEJA
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
